NICE TA620 replaces NICE TA381 for maintenance treatment of relapsed platinum-sensitive ovarian fallopian tube and peritoneal cancer. (Decision date - February 2020)
NICE TA598 - maintenance treatment of BRCA mutation-positive advanced ovarian,
fallopian tube or peritoneal cancer. (Decision date - September 2019)
NICE TA693 - Olaparib plus bevacizumab for
maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal
cancer (Decision date - May 2021)
for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer. NHSE commissioned (Decision date - May 2023)
NICE TA886 - Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy. (Decision date - June 2023)
NICE TA887 - Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer. (Replaces TA831) (Decision date - June 2023)
NICE TA908 - Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (managed access review of NICE TA620) (Decision date - Aug 2023)
NICE TA946 - Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. NHSE commissioned (Decision date - February 2024)
NICE TA951 - Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer. NHSE commissioned. (Decision date - March 2024)
NICE TA962 - For maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy. NHSE commissioned. (Decision date - April 2024)
NICE TA1040: Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (decision date March 25)
DNP:
NICE TA750 - Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) (Decision date - February 2022)
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
